Absence of IL-12RΒ2 in CD33 + CD38 + pediatric acute myeloid leukemia cells favours progression in NOD/SCID/IL2RγC- deficient mice

E. Ferretti, D. Montagna, E. Di Carlo, C. Cocco, D. Ribatti, E. Ognio, C. Sorrentino, D. Lisini, A. Bertaina, F. Locatelli, V. Pistoia, I. Airoldi

Research output: Contribution to journalArticle

Abstract

Childhood acute myeloid leukemia (AML) is a hematological malignancy in which tumor burden is continuously replenished by leukemic-initiating cells (ICs), which proliferate slowly and are refractory to chemotherapeutic agents. We investigated whether interleukin (IL)-12, an immuno-modulatory cytokine with anti-tumor activity, may target AML blasts (CD45 CD33 ) and populations known to contain leukemia ICs (that is, CD34 CD38 , CD33 CD38 and CD44 CD38 cells). We demonstrate for the first time that: i) AML blasts and their CD34 CD38 , CD33 CD38 , CD44 CD38 subsets express the heterodimeric IL-12 receptor (IL-12R), ii) AML cells injected subcutaneously into NOD/SCID/Il2rg / (NSG) mice developed a localized tumor mass containing leukemic ICs and blasts that were virtually eliminated by IL-12 treatment, iii) AML cells injected intravenously into NSG mice engrafted within the first month in the spleen, but not in bone marrow or peripheral blood. At this time, IL-12 dramatically dampened AML CD45 CD33 , CD34 CD38 , CD33 CD38 and CD44 CD38 populations, only sparing residual CD33 CD38 cells that did not express IL-12RΒ2. From 30 to 60 days after the initial inoculum, these IL-12-unresponsive cells expanded and metastasized in both control and IL-12-treated NSG mice. Our data indicate that the absence of IL-12RΒ2 in pediatric AML cells favours leukemia progression in NOD/SCID/IL2Rγc-deficient mice.

Original languageEnglish
Pages (from-to)225-235
Number of pages11
JournalLeukemia
Volume26
Issue number2
DOIs
Publication statusPublished - Feb 2012

Fingerprint

Interleukins
Myeloid Cells
Acute Myeloid Leukemia
Interleukin-12
Pediatrics
SCID Mice
Leukemia
Interleukin-12 Receptors
Hematologic Neoplasms
Tumor Burden
Population
Neoplasms
Spleen
Bone Marrow
Cytokines

Keywords

  • AML
  • cytokine receptor
  • cytokines

ASJC Scopus subject areas

  • Hematology
  • Cancer Research
  • Anesthesiology and Pain Medicine

Cite this

Absence of IL-12RΒ2 in CD33 + CD38 + pediatric acute myeloid leukemia cells favours progression in NOD/SCID/IL2RγC- deficient mice. / Ferretti, E.; Montagna, D.; Di Carlo, E.; Cocco, C.; Ribatti, D.; Ognio, E.; Sorrentino, C.; Lisini, D.; Bertaina, A.; Locatelli, F.; Pistoia, V.; Airoldi, I.

In: Leukemia, Vol. 26, No. 2, 02.2012, p. 225-235.

Research output: Contribution to journalArticle

Ferretti, E. ; Montagna, D. ; Di Carlo, E. ; Cocco, C. ; Ribatti, D. ; Ognio, E. ; Sorrentino, C. ; Lisini, D. ; Bertaina, A. ; Locatelli, F. ; Pistoia, V. ; Airoldi, I. / Absence of IL-12RΒ2 in CD33 + CD38 + pediatric acute myeloid leukemia cells favours progression in NOD/SCID/IL2RγC- deficient mice. In: Leukemia. 2012 ; Vol. 26, No. 2. pp. 225-235.
@article{07a9ea25a6aa45b882e1339f322baf41,
title = "Absence of IL-12RΒ2 in CD33 + CD38 + pediatric acute myeloid leukemia cells favours progression in NOD/SCID/IL2RγC- deficient mice",
abstract = "Childhood acute myeloid leukemia (AML) is a hematological malignancy in which tumor burden is continuously replenished by leukemic-initiating cells (ICs), which proliferate slowly and are refractory to chemotherapeutic agents. We investigated whether interleukin (IL)-12, an immuno-modulatory cytokine with anti-tumor activity, may target AML blasts (CD45 CD33 ) and populations known to contain leukemia ICs (that is, CD34 CD38 , CD33 CD38 and CD44 CD38 cells). We demonstrate for the first time that: i) AML blasts and their CD34 CD38 , CD33 CD38 , CD44 CD38 subsets express the heterodimeric IL-12 receptor (IL-12R), ii) AML cells injected subcutaneously into NOD/SCID/Il2rg / (NSG) mice developed a localized tumor mass containing leukemic ICs and blasts that were virtually eliminated by IL-12 treatment, iii) AML cells injected intravenously into NSG mice engrafted within the first month in the spleen, but not in bone marrow or peripheral blood. At this time, IL-12 dramatically dampened AML CD45 CD33 , CD34 CD38 , CD33 CD38 and CD44 CD38 populations, only sparing residual CD33 CD38 cells that did not express IL-12RΒ2. From 30 to 60 days after the initial inoculum, these IL-12-unresponsive cells expanded and metastasized in both control and IL-12-treated NSG mice. Our data indicate that the absence of IL-12RΒ2 in pediatric AML cells favours leukemia progression in NOD/SCID/IL2Rγc-deficient mice.",
keywords = "AML, cytokine receptor, cytokines",
author = "E. Ferretti and D. Montagna and {Di Carlo}, E. and C. Cocco and D. Ribatti and E. Ognio and C. Sorrentino and D. Lisini and A. Bertaina and F. Locatelli and V. Pistoia and I. Airoldi",
year = "2012",
month = "2",
doi = "10.1038/leu.2011.213",
language = "English",
volume = "26",
pages = "225--235",
journal = "Leukemia",
issn = "0887-6924",
publisher = "Nature Publishing Group",
number = "2",

}

TY - JOUR

T1 - Absence of IL-12RΒ2 in CD33 + CD38 + pediatric acute myeloid leukemia cells favours progression in NOD/SCID/IL2RγC- deficient mice

AU - Ferretti, E.

AU - Montagna, D.

AU - Di Carlo, E.

AU - Cocco, C.

AU - Ribatti, D.

AU - Ognio, E.

AU - Sorrentino, C.

AU - Lisini, D.

AU - Bertaina, A.

AU - Locatelli, F.

AU - Pistoia, V.

AU - Airoldi, I.

PY - 2012/2

Y1 - 2012/2

N2 - Childhood acute myeloid leukemia (AML) is a hematological malignancy in which tumor burden is continuously replenished by leukemic-initiating cells (ICs), which proliferate slowly and are refractory to chemotherapeutic agents. We investigated whether interleukin (IL)-12, an immuno-modulatory cytokine with anti-tumor activity, may target AML blasts (CD45 CD33 ) and populations known to contain leukemia ICs (that is, CD34 CD38 , CD33 CD38 and CD44 CD38 cells). We demonstrate for the first time that: i) AML blasts and their CD34 CD38 , CD33 CD38 , CD44 CD38 subsets express the heterodimeric IL-12 receptor (IL-12R), ii) AML cells injected subcutaneously into NOD/SCID/Il2rg / (NSG) mice developed a localized tumor mass containing leukemic ICs and blasts that were virtually eliminated by IL-12 treatment, iii) AML cells injected intravenously into NSG mice engrafted within the first month in the spleen, but not in bone marrow or peripheral blood. At this time, IL-12 dramatically dampened AML CD45 CD33 , CD34 CD38 , CD33 CD38 and CD44 CD38 populations, only sparing residual CD33 CD38 cells that did not express IL-12RΒ2. From 30 to 60 days after the initial inoculum, these IL-12-unresponsive cells expanded and metastasized in both control and IL-12-treated NSG mice. Our data indicate that the absence of IL-12RΒ2 in pediatric AML cells favours leukemia progression in NOD/SCID/IL2Rγc-deficient mice.

AB - Childhood acute myeloid leukemia (AML) is a hematological malignancy in which tumor burden is continuously replenished by leukemic-initiating cells (ICs), which proliferate slowly and are refractory to chemotherapeutic agents. We investigated whether interleukin (IL)-12, an immuno-modulatory cytokine with anti-tumor activity, may target AML blasts (CD45 CD33 ) and populations known to contain leukemia ICs (that is, CD34 CD38 , CD33 CD38 and CD44 CD38 cells). We demonstrate for the first time that: i) AML blasts and their CD34 CD38 , CD33 CD38 , CD44 CD38 subsets express the heterodimeric IL-12 receptor (IL-12R), ii) AML cells injected subcutaneously into NOD/SCID/Il2rg / (NSG) mice developed a localized tumor mass containing leukemic ICs and blasts that were virtually eliminated by IL-12 treatment, iii) AML cells injected intravenously into NSG mice engrafted within the first month in the spleen, but not in bone marrow or peripheral blood. At this time, IL-12 dramatically dampened AML CD45 CD33 , CD34 CD38 , CD33 CD38 and CD44 CD38 populations, only sparing residual CD33 CD38 cells that did not express IL-12RΒ2. From 30 to 60 days after the initial inoculum, these IL-12-unresponsive cells expanded and metastasized in both control and IL-12-treated NSG mice. Our data indicate that the absence of IL-12RΒ2 in pediatric AML cells favours leukemia progression in NOD/SCID/IL2Rγc-deficient mice.

KW - AML

KW - cytokine receptor

KW - cytokines

UR - http://www.scopus.com/inward/record.url?scp=84856751793&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84856751793&partnerID=8YFLogxK

U2 - 10.1038/leu.2011.213

DO - 10.1038/leu.2011.213

M3 - Article

C2 - 21844875

AN - SCOPUS:84856751793

VL - 26

SP - 225

EP - 235

JO - Leukemia

JF - Leukemia

SN - 0887-6924

IS - 2

ER -